“Although they do not currently have regulatory approval, we analyzed published data on anti-nerve growth factor treatments for OA and included the evidence tables in the formal voting session,” write the authors. “Anti-[nerve growth factors] showed benefits on pain and functional outcomes in patients with knee and hip OA; they were, however, associated with a higher rate of specific adverse events, such as paresthesia.” Thus, the use of anti-nerve growth factor treatments is not recommended.
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Reference
- Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Jul 3. pii: S1063-4584(19)31116-1. [Epub ahead of print]